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Abstract
Background: There has been an international shift in health care, which has seen an increasing focus and development of
technological and personalized at-home interventions that aim to improve health outcomes and patient-clinician communication.
However, there is a notable lack of empirical evidence describing the preparatory steps of adapting and implementing technology
of this kind across multiple countries and clinical settings.
Objective: This study aimed to describe the steps undertaken in the preparation of a multinational, multicenter randomized
controlled trial (RCT) to test a mobile phone–based remote symptom monitoring system, that is, Advanced Symptom Management
System (ASyMS), designed to enhance management of chemotherapy toxicities among people with cancer receiving adjuvant
chemotherapy versus standard cancer center care.
Methods: There were 13 cancer centers across 5 European countries (Austria, Greece, Ireland, Norway, and the United Kingdom).
Multiple steps were undertaken, including a scoping review of empirical literature and clinical guidelines, translation and linguistic
validation of study materials, development of standardized international care procedures, and the integration and evaluation of
the technology within each cancer center.
Results: The ASyMS was successfully implemented and deployed in clinical practices across 5 European countries. The rigorous
and simultaneous steps undertaken by the research team highlighted the strengths of the system in clinical practice, as well as the
clinical and technical changes required to meet the diverse needs of its intended users within each country, before the commencement
of the RCT.
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Conclusions: Adapting and implementing this multinational, multicenter system required close attention to diverse considerations
and unique challenges primarily related to communication and clinical and technical issues. Success was dependent on collaborative
and transparent communication among academics, the technology industry, translation partners, patients, and clinicians as well
as a simultaneous and rigorous methodological approach within the 5 relevant countries.
(JMIR Cancer 2019;5(1):e10813)  doi: 10.2196/10813
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Introduction
Background
The expanding field of electronic health (eHealth) and the global
deployment of technology within health care have become more
apparent over 20 years of research [1-4]. The increase in
technological capabilities has led to many promising eHealth
advancements in the cancer setting. For instance, an increasing
number of health care initiatives in cancer care have utilized
patients’ self-reports to facilitate remote symptom monitoring
[5-11]. With regard to conducting empirical research on this
scale in this field, there is an increasing awareness of the
importance of preliminary work in preparation for large publicly
funded randomized controlled trials (RCTs) [12]. This
preliminary study allows a research team to make judgments
about an eHealth system, and such preparation can facilitate
researcher readiness for full-scale implementation [13]. While
multinational research to evaluate the effectiveness of eHealth
may present several opportunities and important findings, there
are also a number of challenges and considerations when
conducting research involving multiple countries, including
differences in clinical settings such as resources and workflow,
language and translation issues, as well as cultural and societal
differences [14].
Moreover, conducting cross-cultural, multinational eHealth
research requires collaboration and multiple considerations to
ensure an eHealth system’s validity, fidelity, and appropriateness
within different cultural and clinical settings [15-17]. This paper
seeks to address an important gap in knowledge regarding the
steps involved in adapting an eHealth system within cancer care
across multiple countries. This gap may be in part because of
the fact that eHealth remains a relatively new area of research
characterized by exploratory studies implementing novel
technology in cancer care practice and assessing their feasibility
in a single country [18-22].
In this paper, the steps employed to adapt and implement a
mobile phone–based remote symptom monitoring system, the
Advanced Symptom Management System (ASyMS), into
European cancer care before its deployment in a multinational
RCT involving 13 cancer centers across 5 countries (ie, Norway,
Austria, Greece, Ireland, and the United Kingdom) are
described. We detail the robust, structured, and systematic
approach to the adaption of the system and its controlled
implementation at multiple cancer centers across Europe. The
valuable points of learning arising from implementing this
unique eHealth system on such a large multinational scale for
future researchers will also be discussed.
Advanced Symptom Management System
The ASyMS is an eHealth system that has undergone several
years of testing, development, and evaluation [23-29] to monitor
and help patients with cancer manage their chemotherapy-related
symptoms at home. Although previously tested and studied in
the United Kingdom, the ASyMS is currently being studied at
a multinational level for the first time as an RCT—study title:
Electronic Symptom Management using Advanced Symptom
Management System (ASyMS) Remote Technology for Patients
With Cancer (eSMART). The protocol for the study has been
previously published [30]. The purpose of undertaking the steps
described in this paper was to examine and ensure cancer
centers’ technological readiness before commencing the RCT.
The ASyMS is a purpose-built, mobile phone–based remote
symptom monitoring system to enable real-time, 24-hour
monitoring and management of patients’ self-reported
chemotherapy-related toxicities. The ASyMS is hosted by the
eSMART Consortium technological partner, Docobo. The core
component of the ASyMS is the mobile phone device, that is,
the ASyMS patient handset (Figure 1).
Patients are required to complete a symptom
questionnaire—Chemotherapy Toxicity Self-Assessment
Questionnaire—once a day, which is a patient-related outcome
measure, developed by the ASyMS research team to facilitate
rapid and accurate daily assessments of chemotherapy toxicity
in clinical practice [31]. The questionnaire assesses 10 specific
chemotherapy-related symptoms (ie, nausea, vomiting, diarrhea,
constipation, hand-foot syndrome, mucositis, paresthesia,
flu-like symptoms, fatigue, and pain). Additionally, if patients’
existing symptoms escalate or new symptoms are experienced,
they can be reported using the ASyMS patient handset. The
ASyMS analyses the information using an integrated clinical
risk algorithm, as shown in The ASyMS Care Pathway (Figure
2), which initiates an alert to the clinical team at the patient’s
cancer center. The ASyMS involves 3 types of alerts [30]:
1. A green alert is activated when a patient reports symptom
that can be managed at home, without requiring current
clinical intervention, using self-care advice by a clinician.
2. An amber alert is sent to a clinician if patients’ symptoms
are bordering on becoming problematic and are responsive
to early preventative interventions. Amber alerts are to be
addressed within 8 hours by a clinician.
3. A red alert is sent to a clinician if patients’ symptoms are
severe or life-threatening. Red alerts are to be addressed
within 30 minutes.
JMIR Cancer 2019 | vol. 5 | iss. 1 | e10813 | p. 2http://cancer.jmir.org/2019/1/e10813/
(page number not for citation purposes)
Furlong et alJMIR CANCER
XSL•FO
RenderX
Figure 1. The Advanced Symptom Management System patient handset.
Figure 2. The Advanced Symptom Management System care pathway.
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Figure 3. The Advanced Symptom Management System clinician handset.
The ASyMS patient handset contains an in-built library that
generates self-care advice each time a patient completes the
questionnaire, specific to the experienced symptoms. The
self-care library and graphical depiction of their symptoms can
be viewed by patients at any time.
For any symptom that requires clinical intervention (amber or
red alerts), the algorithm generates real-time alerts to the cancer
center via a dedicated ASyMS clinician handset (Figure 3). This
specialized mobile phone–based clinician handset is carried by
an alert handler (ie, clinician) at all times to receive alerts. Once
an alert is received, the alert handler views the patient’s
real-time symptom reports on a secure stand-alone ASyMS
clinician website before contacting the patient to initiate the
appropriate care intervention.
Alert handlers can access patients’ symptom reports,
demographic and clinical information, contact telephone
numbers, and addresses to facilitate an initial telephone
assessment with the patient. Clinicians can store summaries of
alert outcomes in the patients’ local medical records. Clinical
algorithms based on international, national, and local guidelines
as well as feedback from clinicians and patients determine the
appropriate standardized interventions for the type of alert
generated. The alert handler documents the intervention in the
patients’ clinical case notes.
Methods
In preparation for the use of the ASyMS within a multinational,
multicenter RCT, the following steps were undertaken.
Scoping Review
Although the ASyMS was rigorously developed and empirically
studied previously in the United Kingdom [23-29], in order to
upscale the system to various European countries, a scoping
review was undertaken to ensure that it is consistent with
international, national, and relevant local guidelines for assessing
and managing the most common chemotherapy-related
symptoms. This review that included evidence on the
management of chemotherapy toxicity within Europe
(assessment, management, and self care) was published [32].
Following the scoping review, the assessment, management
interventions (including responses to alerts), and self care for
the ASyMS were agreed upon by the research team using a
consultation exercise undertaken with clinicians (clinical
advisory group) and patients (patient advisory group) at the
participating cancer centers to ensure standardized practice
across all cancer centers.
Translation and Linguistic Validation of the Advanced
Symptom Management System Materials
Given that the ASyMS would be used simultaneously within 5
different European countries, it was paramount that all the study
materials were translated and validated linguistically for use in
non-English speaking countries. The ASyMS and all related
study documents were to be available in German, Norwegian,
and Greek. Although a majority of outcome measures were
previously available in the language of the participating
countries, some required translation for their use in the ASyMS.
The International Society for Pharmacoeconomics and Outcomes
Research (ISPOR) Patient-Reported Outcomes Translation and
Linguistic Validation Task Force guidelines [33] were used to
guide the translation and validation process. Included in the
translation process were the following:
• The ASyMS clinician website
• The ASyMS patient handset
• The ASyMS clinician handset
• The ASyMS technical support website
• Patient-reported outcome measures
• Additional data collection forms and questionnaires
• Supporting documentation, including the study protocol,
patient and clinician documents, and user manuals.
• eSMART research project website
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The 2 key components of the translation process were (1)
translation and linguistic validation of questionnaires into the
required languages for the participating cancer centers and (2)
translation of all additional study components and supporting
documentation into the required languages (eg, patient
information letters and consent forms). The employment of a
translation company was necessary to complete this step. A
total of 4 translation companies were evaluated to undertake
this task based on the following criteria:
1. Compliance with ISPOR translation and validation
guidelines
2. Experience in the translation and validation of
patient-reported outcome measures as documented through
previous collaborations and completed projects beforehand
3. Documented reliability and trustworthiness based on
testimonials
4. Acceptable costs and turnaround times to ensure project
cost-effectiveness
Following this evaluation process, Language Scientific was the
chosen company that translated and linguistically validated the
ASyMS questionnaires based on the robustness of their approach
and costs.
Preparation and Evaluation of Cancer Centers for the
Use of the Advanced Symptom Management System
The preparation and evaluation of the cancer centers for the use
of the ASyMS required an assessment of their technology
infrastructure and human and material resource requirements.
As the ASyMS required simultaneous implementation within
13 cancer centers in 5 countries, monthly teleconferences were
held with all study partners to provide an opportunity to inform,
assess progress, update, and identify any issues in this step. The
teleconferences were attended by representatives in all partner
countries, which facilitated open discussions and necessary
actions around issues including ethics and governance, data
protection, study instruments, technology development, and
language translation processes. Additionally, clinicians and
researchers committed to and participated in monthly
teleconference meetings which were well-attended at this stage
of implementation to discuss practical, clinical, and technical
issues of using the ASyMS at each cancer center.
Before the selection of each cancer center to participate in the
RCT, the reliability of Wi-Fi and mobile data networks was
assessed at each cancer center. This assessment was conducted
by Docobo using a Connectivity Logger app, which was run on
Motorola Moto g mobile handsets at each of the participating
cancer centers. All the handsets were procured by Docobo,
marked with an individual tracking number, uploaded with the
ASyMS, and distributed to each cancer center. Each research
nurse, clinician, and research assistant was provided with
training on the ASyMS, this included education regarding how
the ASyMS works, patient registration, and alert handling. They
were then registered with individual log-ins on the ASyMS,
with the appropriate functions of patient registration and alert
handling. Subsequently, researchers at each cancer center
managed the handsets and provided them to the patients when
recruited to the feasibility study.
An assessment of the ASyMS technological readiness with
cancer care practice was necessary before its use in the RCT.
This was undertaken with a small sample (n=64) of the intended
population for the RCT across the 13 cancer centers. Data
captured (eg, patient completion of the daily questionnaire,
clinician initial response times to alerts, and clinician handling
times of alerts) were used to assess the readiness of each cancer
center to begin the RCT. All feasibility data were extracted from
the study’s secure database hosted by Docobo. Technological
readiness was assessed and confirmed using 2 Technological
Feasibility Evaluation forms developed by the study
investigators—1 for clinicians using the ASyMS (Multimedia
Appendix 1) and 1 for Docobo (Multimedia Appendix 2) to
complete. The 3 key parameters of technological readiness set
out in the study protocol were examined:
1. System set-up: to assess whether clinicians and researchers
had received sufficient training on the ASyMS, were able
to register participants to use the ASyMS (using handset,
tablet, and personal computer), and were confident to
educate and register a new patient on a handset.
2. Data transfer: to assess whether data were successfully
transferred between the ASyMS patient and clinician
handsets, electronic clinical case note reviews, and the study
server. It was essential that all handsets (ie, patient handsets
and clinician handsets) had the required mobile or Wi-Fi
connectivity for the intervention to be safe and effective.
3. Usability issues: to assess whether the patients could use
the ASyMS patient handset, as well as the clinicians’ ability
to use the ASyMS clinician handset, log on to the ASyMS
clinician website, handle patient alerts, and complete
medical reviews at the end of the patients’ chemotherapy
cycle. The ASyMS technical support website, from both
the clinician’s and patient’s perspective, was also evaluated.
On completion of the technological readiness assessment at
each cancer center, a representative from the cancer center and
the technological partner were required to complete their
respective Technological Feasibility Evaluation forms, which
were subsequently checked by the ASyMS research team for
any discrepancies that needed to be addressed.
Results
The Findings
ASyMS was successfully adapted and implemented at 11 cancer
centers across 5 European countries. The system was fully
prepared for its deployment at each cancer center in providing
care to their patients before commencing its large-scale RCT.
The findings from each step of the adaption and implementation
process will now be outlined.
Scoping Review
The findings from the scoping review were used to update the
self-care advice within the ASyMS and refine the clinical risk
algorithms for the alerting system. Following the completion
of the scoping review, a consultation exercise was undertaken
with clinicians (clinical advisory group) and patients (patient
advisory group) at the participating cancer centers [32]. The
review found discrepancies among the published literature and
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the clinical advisory groups regarding the treatment of febrile
neutropenia (fever) and what temperature rating was considered
to warrant medical attention. It was concluded to use the most
conservative scenario for safety reasons (37.5 Celsius) [32].
Translation and Validation of Study Materials
The questionnaires and related documents involved in the
ASyMS were successfully translated into the required languages.
Minor queries were raised by the chosen translation company
regarding specific items on the study questionnaires for Greek
and Norwegian translation. The company sought confirmation
from the research team to proceed with slight modifications of
questionnaire items based on the feedback from the cognitive
debriefing participants to ensure that they were culturally
appropriate.
The translation involved 3 translation rounds and interviews
with lay people in the respective countries (Austria, Greece,
and Norway) in accordance with the current guidelines outlined
by the ISPOR [33], which involved forward and back translation.
For each component of the ASyMS, the information technology
interface and documentation were adapted and translated for
clinical use. Once the intervention content was translated and
validated, ethical approval was obtained from the relevant ethics
committees in all of the cancer centers across the 5 participating
countries, as detailed in the protocol publication [30].
Assessment of the Cancer Centers’ Technological
Infrastructure
A crucial component of the implementation of the ASyMS at
cancer centers was the assessment of technological readiness,
which was undertaken by Docobo. The Connectivity Logger
app, installed on the ASyMS clinician handset, measured and
logged the quality of mobile and Wi-Fi networks at 1-min
intervals while the handset was being carried by clinicians
during their working hours. Areas in a cancer center where the
clinician handset could not access Wi-Fi or a mobile data
network were identified. The connectivity information was
analyzed by Docobo. Clinicians were required to log at least
12 hours of mobile data and Wi-Fi.
The primary criterion for the connectivity assessment was the
maximum sustained period for which no communication over
the mobile network (ie, neither mobile internet protocol or text
communications) was possible, being no more than 15 minutes
(target response time was 30 minutes). The secondary factors
considered were the distribution of signal strength and the
quality of the mobile data connection. Analysis showed that at
most cancer centers, the connectivity environment was favorable
in providing a reliable communication channel to the ASyMS
clinician handset. However, 1 cancer center had a loss of
connectivity for up to 20 minutes (based on 800 hours of testing)
compared with other cancer centers that had between 5 and 12
min of lack of connectivity. The Docobo team visited the cancer
center to investigate the cause and concluded that the lack of
connectivity occurred in the corridors of the cancer center and
not on the relevant oncology ward, where suboptimal
connectivity forced the handset to connect to a weak mobile
network. Given the potential impact on clinical care should an
alert not be received on time because of lack of connectivity,
all clinician handsets needed to monitor for and make clinicians
aware of a loss of network connectivity. Changes were made
to the ASyMS, which could monitor the clinician handset at all
times and make clinicians aware, via automated short message
service text messaging and email, when a handset lost
connectivity. It was concluded that 2 active handsets were
necessary at each cancer center, with one in use and the second
on charge, to allow for efficient charging and thus ensuring
clinicians could hold the handset with 24-hour coverage as
required.
Feasibility Study of the Advanced Symptom
Management System at European Cancer Centers
A total of 13 cancer centers across 5 European countries (ie,
Austria, Greece, Ireland, Norway, and the United Kingdom)
participated in the feasibility study. During this testing phase,
64 patients consented to use the ASyMS over 1 cycle of
chemotherapy. At each cancer center, 2 patients per cancer type
(not all cancer centers included all 3 patient populations) were
recruited to test the system. Inclusion and exclusion criteria are
detailed in Textbox 1 and Textbox 2, and patient numbers per
diagnosis at the different European cancer centers are shown in
Table 1.
Textbox 1. Participant eligibility inclusion criteria.
• Adults (≥18 years)
• Diagnosed with breast cancer, colorectal cancer, Hodgkin’s disease, or non-Hodgkin’s lymphoma
• Currently receiving or about to start first-line chemotherapy
• Scheduled to receive 2, 3, or 4 weekly chemotherapy protocols (ie, chemotherapy administered every 14, 21, or 28 days, respectively)
• Scheduled to receive 1 cycle of chemotherapy
• Physically or psychologically fit to participate in the study
• Able to understand and communicate in the respective language
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Textbox 2. Participant eligibility exclusion criteria.
• Diagnosed with a distant metastasis in the case of breast cancer or colorectal cancer
• Experiencing B symptoms in the context of a Hodgkin’s disease or non-Hodgkin’s lymphoma diagnosis
• Scheduled to receive concurrent radiotherapy
• Scheduled to receive weekly chemotherapy
• Diagnosed with recurrent cancer
• Patients who have had chemotherapy within the previous 5 years for any medical reason
• Unable to provide written informed consent
Table 1. Patients recruited to conduct the feasibility study at each cancer center.
Hematological, nColorectal, nBreast, nStudy Center
222Cancer Center 1: Austria
122Cancer Center 2: United Kingdom
—
a22Cancer Center 3: United Kingdom
222Cancer Center 4: United Kingdom
222Cancer Center 5: United Kingdom
—22Cancer Center 6: Greece
—22Cancer Center 7: Greece
222Cancer Center 8: Greece
—22Cancer Center 9: Ireland
—22Cancer Center 10: Ireland
222Cancer Center 11: Ireland
122Cancer Center 12: Ireland
—22Cancer Center 13: Norway
122626Total
aThese sites did not recruit participants with hematological cancer.
Participants
Data on the testing of the ASyMS at each cancer center were
collated by Docobo and analyzed by the members of the author
team. Across all cancer centers, 85% (64/75) of eligible patients
agreed to participate (Figure 4). Those who declined to
participate cited being too busy, feared the study would increase
worry and stress about the diagnosis or had concerns about
using technology, and they also added that using the handset
may be a burden.
The analysis showed that 62 participants completed the
feasibility study. Furthermore, 2 patients were withdrawn during
the course of the feasibility study, 1 because of technical
difficulties and the other because their chemotherapy treatment
was discontinued. Completion of the daily symptom
questionnaire on the ASyMS patient handset was high, with
patients using it 87.36% (1064/1218) of the time. A 1-way
between-groups analysis of variance showed no statistically
significant differences in adherence rates (P=.15) across
countries (United Kingdom=83.1% [349/420], Ireland=90.2%
[284/315], Norway=85.7% [60/70], Greece=86.8% [249/287],
and Austria=96.8% [122/126]). Similarly, no differences were
found in the adherences rates (P=.47) for completing the daily
questionnaire by cancer type (breast cancer=87.9% [449/511],
colorectal cancer=90.7% [400/441], and hematological
cancers=80.8% [215/266]).
Alert Handling
Across all 13 European cancer centers, a total of 157 amber and
139 red alerts were generated by participants during the
feasibility study. Patients with hematological cancers generated
an average of 1.25 red alerts per person, those with colorectal
cancer had an average of 2.3 red alerts, and those with breast
cancer had 2.4 red alerts. Amber alerts followed a similar
pattern: patients with hematological cancers generated an
average of 2.6 amber alerts, those with colorectal cancer had
an average of 2 amber alerts, and those with breast cancer had
2.8 amber alerts.
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Figure 4. Patient recruitment.
On an average, it took 38.26 min (SD 138) to handle an amber
alert and 15.7 min (SD 20) to handle a red alert. During the
monthly trial management meetings, clinicians and researchers
across all 5 countries agreed that the timeframe for handling
amber alerts (ie, mild to moderate patient symptoms) should be
changed from 4 to 8 hours. In addition, clinicians recommended
modifications to the ASyMS algorithm regarding the symptom
of mucositis (ie, painful inflammation and ulceration of the
mouth and throat). It became apparent that clinicians were
receiving numerous alerts from patients about mucositis. Even
with prompt and appropriate interventions, mucositis takes time
to improve. Consequently, patients reported this symptom over
multiple days, which triggered an alert to the clinician based
on the clinical algorithm. The alert remained active even after
it had been handled and patients were given appropriate
information and clinical interventions. The algorithm was
modified, clinicians were alerted to a patient’s initial report of
mucositis, and depending on the severity, subsequent alerts
were silenced for 1 or 2 days, allowing time for the intervention
to relieve symptoms after the alert was initially handled. The
modifications required technical changes in the ASyMS and
subsequent simultaneous ethical amendments at all participating
cancer centers in order to implement the changes.
Technical Issues
The ASyMS has a dedicated technical support website for
clinicians and researchers to report technical problems and solve
issues. This platform allowed users to log, solve, and track issues
that arose during the feasibility study. A total of 112 issues were
reported during this period. The ASyMS technical support
website facilitated rapid and tailored responses, as well as acted
as a transparent record of correspondence on technological
issues. The most common issues were in relation to using the
ASyMS clinician website (31.3% [35/112]), which is the
Web-based platform for clinicians and researchers to enroll
patients, handle alerts, and monitor feasibility progress.
Additionally, 25% (28/112) of the issues were related to the
ASyMS clinician handset and 18.8% (21/112) were related to
the ASyMS patient handset. All the issues were rectified at each
cancer center by the technology partner, who provided additional
training on using the system, before progression to the RCT.
Technological Readiness of the Advanced Symptom
Management System at European Cancer Centers
The technological readiness of each cancer center was based
on 3 key parameters: system setup, data transfer, and usability
issues. Following the completion of the feasibility study, each
cancer center was evaluated for readiness to move onto the
RCT, using the Technological Feasibility Evaluation Checklists
(Multimedia Appendices 1 and 2). Of the 13 cancer centers, 11
passed the technological feasibility evaluation successfully. It
was notable that of the 13 cancer centers that completed the
feasibility study, 2 reported the intervention was not feasible to
integrate into clinical practice (ie, 1 cancer center in the United
Kingdom and 1 in Ireland). Both cancer centers were unable to
participate because of organizational issues, namely lack of
staffing resources to facilitate 24-hour clinician alert handling
and technology connectivity issues.
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Of the 11 cancer centers that progressed to undertake the RCT,
discrepancies existed between reports by the technology
company and reports by the cancer centers. Discrepancies
included issues involving Wi-Fi and mobile connectivity, local
firewall regulations, clinicians’ log-ins, patient enrollment, and
completion of patient case note reviews. These issues were
investigated and resolved by the researchers at University
College Dublin (AB and AD). Following the feasibility study
and the evaluation of each cancer center, the principal clinical
investigator received a letter from the chief investigator with
formal confirmation of permission to progress to the RCT for
those 11 cancer centers.
Discussion
Principal Findings
This paper details the steps of adapting and implementing a
mobile phone–based remote symptom monitoring system at
multiple cancer centers across several European countries in
preparation for an RCT. Our focus was to outline the
complexities involved in preparing, adapting, and implementing
an eHealth intervention for an RCT at a multinational scale.
The ASyMS has now been adapted and implemented
successfully at 11 cancer centers across 5 European countries
(ie, Austria, Greece, Ireland, Norway, and the United Kingdom).
It is currently being deployed and evaluated in clinical practice
at these cancer centers as part of an RCT.
The undertaking of multinational and multicenter eHealth
research requires several considerations to address the
complexities involved in capturing electronic data [14,34], and
researchers in this study faced diverse and unique challenges.
While adopting the rigorous and simultaneous steps outlined
across Europe, 4 key points of learning emerged, which may
provide valuable information for future researchers
implementing eHealth studies locally, across cultures and at
multiple cancer centers.
Given the multifaceted nature of eHealth [35,36], it was
necessary to ensure that the ASyMS was clinically safe and
technologically secure at each cancer center before conducting
the RCT. Significant time was needed to ensure the European
integration of the ASyMS in preparation for its intended RCT.
Although the ASyMS was based on preliminary work in the
United Kingdom [23-29], the revision and adaptation of the
system to make it applicable across multiple European cancer
centers involved significant input. Implementation of the
ASyMS was achieved through collaborative work with European
study partners and a robust, iterative process to resolve problems
in each cancer center. Technological Feasibility Evaluation
Checklists (Multimedia Appendices 1 and 2) provided effective
quality assurance across all cancer centers. The checklists
provided a detailed and transparent method of ensuring that
each cancer center was suitable to progress to conduct the RCT.
The checklists established that the ASyMS was being
independently evaluated by clinicians and the technology partner
on the same key issues. These enabled the assurance that both
clinical and technical issues were being assessed and the issues
reported were effectively addressed by the research team.
Although 112 issues were reported during the feasibility study,
we feel this number is low considering this was across 13 cancer
centers and that the technology had not been used before in
practice by the clinicians involved. The identification of issues,
which could have only been identified through the use of the
ASyMS in practice, were not foreseen during the adaption of
the system. We would encourage researchers in the field to use
and modify the checklists to suit individual study needs, given
that each study will have its own set of unique clinical and
technical requirements.
As outlined, the questionnaires used in the ASyMS, risk
algorithm, and alert management design were refined based on
the consultation process, which occurred following the scoping
review. This consultation approach aligns with the evidence
that advocates the inclusion of clinician and patient consultation
is more likely to lead to research that will translate into clinical
practice [37,38]. In particular, patient involvement in clinical
research is important to ensure that the correct research questions
are being asked to address the patients’ and public’s needs [39].
Patient (n=15) and clinician advisory groups (n=21) informed
the content of the symptom questionnaires, symptom protocols,
clinical algorithms, and self-care advice to ensure consensus
across the multiple European cancer centers. The scoping review
combined with feedback from clinician and patient advisory
groups provided valuable information, which enabled agreement
among study partners on the format and content of the
intervention, as well as making it current, evidence-based, and
culturally sensitive.
Moreover, the content of the ASyMS had to reflect not only
current international standards but also be delivered in the
appropriate language. A substantial methodological challenge
for cross-cultural research is the standardization of the research
instruments, particularly the translation of instruments without
losing the underlying context or cultural connotations of the
wording [40-42]. This process is often time consuming, but it
is a crucial investment in order to have confidence in the
outcomes of the study. The goal of the translation procedure
was to document that each translation adequately captures the
concepts of the original English-language version and is readily
understood by end users in the target population. We would
encourage fellow researchers and developers of eHealth systems,
who intend to implement in linguistically varied settings, to
factor the time-consuming nature of this step when formulating
study timelines and goals. Additionally, when choosing a
translation company, we recommend that researchers conduct
a scoping exercise of potential candidates to assess their services
that will best suit their study’s requirements including a number
of criteria: compliance with ISPOR translation and validation
guidelines [33]. It is important to consider the company’s
experience with translating similar questionnaires and
documents with previous research collaborations and completed
research projects, reliability and trustworthiness based on
testimonials, service costings, and turnaround times to ensure
project cost-effectiveness.
The feasibility study of the ASyMS at each cancer center was
a crucial methodological step in the transition from its adaptation
to implementation into clinical practice. Additional areas were
identified where the technology needed to be modified in order
to meet the diverse needs of both clinicians and patients.
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Following the identification of a number of clinical and technical
key issues and subsequent discussions at trial management group
meetings, the ASyMS was refined and updated to reflect
feedback provided by clinicians, researchers, and technological
partners. This feedback highlighted that a 4-hour response
timeframe was not feasible in busy cancer centers and that the
algorithm for the symptom of mucositis warranted modification
because of its persistent nature and the amount of alerts
clinicians were receiving. Such considerations with the ASyMS
algorithm and its related clinician alerts only became apparent
during its deployment at multiple cancer centers. Thus, we
encourage researchers who intend on conducting multicenter
or multinational research using an eHealth intervention to
conduct a feasibility study at each intended cancer center, as
clinicians and researchers may experience the system differently
at each cancer center or country and thus may identify areas of
concern. One cannot assume a “one-size-fits-all” model
regarding implementing eHealth systems within various clinical
settings. In addition, the feasibility study allowed the research
consortium to identify cancer centers that were unsuitable to
progress to conducting the RCT because of existing heavy
workloads and the perceived complexity of the intervention.
This echoes the importance of testing an intervention in its
intended and various contexts [43], as well as the establishment
of communication pathways that clinicians and researchers can
use to gain first-hand experience about the system [44].
Successfully implementing new clinical practices in real world
settings can be challenging. A significant outcome of the
feasibility study was the establishment of relationships and
communication between the ASyMS research team and the
clinicians at each cancer center. eHealth systems are often
predeveloped by researchers to suit a clinical setting and
clinicians are asked to assist in effectively implementing them
[45]. This approach has been previously criticized as being
ineffective in producing effective translation and sustained
implementation of evidence-based practices [46]. In the case
with the ASyMS, it was vital that strong working relationships
and rapports were developed between the research team and the
clinicians at the cancer centers. The establishment of
relationships between the researchers and clinicians facilitated
patient recruitment, since clinicians became aware of the
participant criteria and notified the research team when a patient
met the inclusion criteria. Additionally, the feasibility study
allowed clinicians to become familiar with the study protocol
and procedures. For example, when participants were recruited,
it was done when they visited the cancer center for
chemotherapy treatment where relationships were already
developed. On the basis of previous research that showed
clinicians’ concern and apprehension about new eHealth
technologies [47-49], the feasibility study of the ASyMS helped
the research team identify clinicians’ concerns and provide
additional training sessions that afforded clinicians the
opportunity to learn about the study protocol [30], express their
concerns, and ask questions about the technology.
Limitations
Although these findings may guide future research in
multinational eHealth research in cancer care and other areas,
the limitations of our approach must also be noted. The cancer
centers approached to take part in the ASyMS research were
deemed clinically and technologically ready to partake in the
research, given that they were teaching hospitals and actively
engaged in other research activity. Thus, the implementation
and deployment of the ASyMS at these cancer centers may not
be representative of other cancer centers that do not have such
research and technological resources. The 2 cancer centers that
did not proceed to the RCT had intended to implement the
ASyMS but did not have the efficient resources (ie, time and
staff). Cancer centers that were averse to technology may not
be represented in this sample. Also, it must be noted that the
feasibility study should be interpreted in the context of another
limitation in that patients were not recruited before the initiation
of chemotherapy. Therefore, some patients were chemotherapy
naïve and others had received previous chemotherapy
treatments, which may have affected the results. However,
despite these limitations, our work provided significant data
around feasibility, changes needed for future use, and the
perceived benefits of such a system in cancer centers.
Conclusions
Patients with cancer who are receiving chemotherapy require
prompt identification of symptoms and interventions to decrease
the symptom burden and enhance their quality of life. Adapting
and implementing a multicenter remote symptom monitoring
eHealth system demands significant and substantial collaborative
preparatory work across multinational settings before the
deployment of an RCT. The findings discussed in this paper
outline the importance of effective collaborative project
management, diligent use of checklists, clear division of
responsibilities with each partner, country, and associated cancer
centers, along with addressing cultural and language requisites
so that the scientific integrity and reproducibility of the study
are assured.
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